Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 03 2023 - 6:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus, today
announced the appointment of Helen M. Boudreau to its Board of
Directors. Ms. Boudreau has more than 30 years of operating
experience in a variety of industries, including the biotechnology
and pharmaceutical sectors, in addition to serving as a director on
numerous public boards.
“We are pleased to welcome Helen to the Cara
board,” said Christopher Posner, President, Chief Executive Officer
and Director of Cara Therapeutics. “We look forward to leveraging
her expertise in finance, commercial operations, and R&D
portfolio management as we continue to work to maximize the
commercial and therapeutic potential of difelikefalin.”
“I’m excited to join the Cara board at this
stage of the company’s development,” said Ms. Boudreau. “As the
company continues executing on its commercial strategy for KORSUVA®
(difelikefalin) injection while driving the clinical development of
oral difelikefalin, I look forward to working with the management
team and board to help fulfill the company’s mission to be the
leader in the treatment of chronic pruritus.”
Prior to her retirement, Ms. Boudreau served as
the Chief Operating Officer of the Bill & Melinda Gates Medical
Research Institute. Over the course of her career, Ms. Boudreau
held financial leadership positions in the biotechnology and
pharmaceutical industries including Chief Financial Officer (CFO)
of Proteostasis Therapeutics; CFO of Novartis Corporation in the
U.S.; global CFO of Novartis Oncology; and senior finance positions
at Pfizer Inc. Prior to joining the biopharmaceutical sector, she
held roles at PepsiCo, McKinsey & Company, and Bank of America.
She currently serves on the board of directors of Premier, Inc.,
Shattuck Labs, and Rallybio. Ms. Boudreau received a B.A. in
Economics from the University of Maryland and an MBA from the
Darden Graduate School of Business at the University of
Virginia.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s KORSUVA® (difelikefalin) injection is the first and only
FDA-approved treatment for moderate-to-severe pruritus associated
with chronic kidney disease in adults undergoing hemodialysis. The
Company is developing an oral formulation of difelikefalin and has
Phase 3 programs ongoing for the treatment of pruritus in patients
with advanced chronic kidney disease and atopic dermatitis. In
addition, the Company has initiated a Phase 2/3 program of oral
difelikefalin for the treatment of moderate-to-severe pruritus in
patients with notalgia paresthetica. For more information, visit
www.CaraTherapeutics.com and follow the company on Twitter,
LinkedIn and Instagram.
Forward-looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Examples of these forward-looking statements include
statements concerning the Company’s ability to successfully execute
its commercialize strategy with respect to KORSUVA injection and
its future development of oral difelikefalin for treatment of
pruritus. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Risks are
described more fully in the Company’s filings with the Securities
and Exchange Commission, including the “Risk Factors” section of
the Company’s Annual Report on Form 10-K for the year ended
December 31, 2022 and its other documents subsequently filed with
or furnished to the Securities and Exchange Commission, including
its Form 10-Q for the quarter ended March 31, 2023. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Cara Therapeutics
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024